REG - FTSE Russell Dechra Pharmaceutcls Persimmon Plc Baillie Gifford US - Dechra Pharmaceuticals
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240111:nRSK4516Za&default-theme=true
RNS Number : 4516Z FTSE Russell 11 January 2024
Further to the FTSE notice released on 09 January 2024
(https://research.ftserussell.com/products/index-notices/home/getnotice/?id=2611255)
in relation to Dechra Pharmaceuticals (UK): Constituent Deletion, please
note the replacement in the fixed indices.
All other details remain unchanged. Please see updated notice below:
Dechra Pharmaceuticals (UK): Constituent Deletion - Update
Changes in FTSE UK Index Series
11 January 2024
Subject to court sanctioning the scheme of arrangement in relation to the cash
offer for Dechra Pharmaceuticals (UK, constituent) by Freya Bidco Limited
(non-constituent), please see details of affected indexes and effective dates
below:
Dechra Pharmaceuticals (UK, 0963318) will be deleted from the index.
Persimmon PLC (UK, 0682538) will be added to the FTSE 100 Index and deleted
from the FTSE 250 Index.
Baillie Gifford US Growth Trust (UK, BDFGHW4) will be added to the FTSE 250
Index and deleted from the FTSE SmallCap Index.
All changes effective from 16 January 2024
Full details of index changes are available on the FTSE Russell website.
For further information please contact FTSE Russell Client Services at
info@ftserussell.com or call:
Australia +61 (0) 2 7228 5659
Hong Kong +852 2164 3333
Japan +81 3 6441 1430
London +44 (0) 20 7866 1810
New York +1877 503 6437
Alternatively please visit our website at lseg.com/ftse-russell
Terms of Use (http://www.ftserussell.com/legal/website-terms-use) | Copyright
© 2024 FTSE Russell
Alternatively please visit our website at lseg.com/ftse-russell
Terms of Use (http://www.ftserussell.com/legal/website-terms-use) | Copyright
© 2024 FTSE Russell
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END FTSFLFLDLIILLIS
- Announcement
- Announcement
- Announcement
- Announcement
- Announcement